Medtronic, Genzyme Lead US Orthopedic Biomaterials Market Due to High R&D Costs Limiting Competition
According to a new series of reports on the U.S. market for orthopedic biomaterials by iData Research (www.idataresearch.com), orthopedic growth factors have a relatively high average selling price (ASP) since their introduction to the market due to the high costs of recombinant growth factor technologies. The high research and development (R&D) costs associated with the growth factor segment provide a barrier to entry against potential competitors.
View full press release